# C_2017242EN.01001901.xml

| 27.7.2017 | EN | Official Journal of the European Union | C 242/19 |
| --- | --- | --- | --- |

27.7.2017

EN

Official Journal of the European Union

C 242/19

---

Prior notification of a concentration

(Case M.8541 — Thermo Fisher Scientific/Patheon)

(Text with EEA relevance)

(2017/C 242/09)

| 1. | On 19 July 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Thermo Fisher Scientific Inc. (‘Thermo Fisher’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the undertaking Patheon N.V. (‘Patheon’, The Netherlands) by way of a purchase of shares. |
| --- | --- |

1.

On 19 July 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Thermo Fisher Scientific Inc. (‘Thermo Fisher’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the undertaking Patheon N.V. (‘Patheon’, The Netherlands) by way of a purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | Thermo Fisher is a manufacturer and supplier of laboratory equipment, analytical instruments, diagnostics, and related products and services. It is headquartered in the US and active internationally. |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Thermo Fisher is a manufacturer and supplier of laboratory equipment, analytical instruments, diagnostics, and related products and services. It is headquartered in the US and active internationally.

| — | Patheon is a contract development and manufacturing organisation, offering active pharmaceutical ingredients and finished drug product services. It is headquartered in the Netherlands and active internationally. |
| --- | --- |

—

Patheon is a contract development and manufacturing organisation, offering active pharmaceutical ingredients and finished drug product services. It is headquartered in the Netherlands and active internationally.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8541 — Thermo Fisher Scientific Inc./Patheon N.V., to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8541 — Thermo Fisher Scientific Inc./Patheon N.V., to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---